Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 113Neoplasm Metastasis 5Carcinoma, Intraductal, Noninfiltrating 5Polycystic Ovary Syndrome 4Ovarian Neoplasms 4Osteoporosis 4Neoplasms 4Infertility 4Breast Neoplasms, Male 4Arthralgia 4Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Pain 2Leiomyosarcoma 2Leiomyoma 2Endometrial Neoplasms 2Cystadenocarcinoma, Serous 2Breast Carcinoma In Situ 2Bone Diseases, Metabolic 2Advanced Breast Cancer 2Uterine Neoplasms 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Cysts 1Osteitis Deformans 1Obesity 1Multiple Endocrine Neoplasia Type 1 1Medullary cystic kidney disease 1 1Lymphoma, Non-Hodgkin 1

Interventions

seribantumab 2zenocutuzumab 1exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1Fulvestrant 1Erlotinib Hydrochloride 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lethal Congenital Contracture Syndrome 2 × Letrozole × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡